Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics Inc., alleging that certain officers and directors breached their fiduciary duties. The investigation centers on accusations that the company overstated its readiness to meet FDA manufacturing compliance requirements and exaggerated the regulatory prospects of its oxylanthanum carbonate new drug application, resulting in potentially false and misleading public statements. Shareholders who purchased shares before March 29, 2024, and still hold them may seek corporate reforms and the return of funds to the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602170915NEWSFILECNPR____20260217_284137_1) on February 17, 2026, and is solely responsible for the information contained therein.